X0704 D/A LIVE 0001479290 Revance Therapeutics, Inc. 7555 GATEWAY BLVD. NEWARK CA CALIFORNIA 94560 510-742-3400 DELAWARE None None Corporation true L. Daniel Browne 7555 Gateway Boulevard Newark CA CALIFORNIA 94560 Executive Officer Director Robert Byrnes 7555 Gateway Boulevard Newark CA CALIFORNIA 94560 Director Phyllis Gardner 7555 Gateway Boulevard Newark CA CALIFORNIA 94560 Director Jim Glasheen 7555 Gateway Boulevard Newark CA CALIFORNIA 94560 Director Frank Kung 7555 Gateway Boulevard Newark CA CALIFORNIA 94560 Director Vicente Trelles 7555 Gateway Boulevard Newark CA CALIFORNIA 94560 Director Pharmaceuticals Decline to Disclose 06 true 0001479290-10-000002 2009-12-08 false true true Offering of Series D Preferred Stock ("Series D"), and the underlying shares of Common Stock issuable upon conversion of the Series D. true $5,666,370.73 of the Issuer?s Series D was issued in exchange for outstanding principal and accrued interest on convertible notes issued by the Company and $30,570,562.22 of the Issuer's Series D was issued in connection with a venture capital financing. 0 36236932 36236932 0 $5,666,370.73 of the Issuer?s Series D was issued in exchange for outstanding principal and accrued interest on convertible notes issued by the Company and $30,570,562.22 of the Issuer's Series D was issued in connection with a venture capital financing false 27 0 0 0 false Revance Therapeutics, Inc. L. Daniel Browne L. Daniel Browne President and CEO 2010-11-17